ATE325122T1 - Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung - Google Patents

Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Info

Publication number: ATE325122T1
Authority: AT; Austria
Prior art keywords: production; therapeutic use; piperazinylacylpiperidine; derivatives; piperazinylacylpiperidine derivatives
Prior art date: 2002-06-07

Application number

AT03757109T

Other languages

English (en)

Inventor

Francoise Bono

Michael Bosch

Santos Victor Dos

Jean Marc Herbert

Dino Nisato

Bernard Tonnerre

Jean Wagnon

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-05

Publication date

2006-06-15

2003-06-05 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE325122T1 publication Critical patent/ATE325122T1/de

Links

230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT03757109T 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung ATE325122T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0207001		2002-06-07

Publications (1)

Publication Number	Publication Date
ATE325122T1 true ATE325122T1 (de)	2006-06-15

Family

ID=29724874

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03757108T ATE336491T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
AT03757109T ATE325122T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03757108T ATE336491T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Country Status (29)

Country	Link
US (2)	US7468368B2 (de)
EP (2)	EP1513835B1 (de)
JP (2)	JP4441401B2 (de)
KR (1)	KR100970812B1 (de)
CN (1)	CN100448875C (de)
AR (2)	AR040246A1 (de)
AT (2)	ATE336491T1 (de)
AU (2)	AU2003255645A1 (de)
BR (1)	BR0311828A (de)
CA (1)	CA2487840C (de)
CY (2)	CY1107330T1 (de)
DE (2)	DE60305037T2 (de)
DK (2)	DK1513835T3 (de)
EA (1)	EA007501B1 (de)
ES (2)	ES2264001T3 (de)
HR (1)	HRP20041157B1 (de)
IS (1)	IS2302B (de)
MA (1)	MA27233A1 (de)
ME (1)	MEP11508A (de)
MX (1)	MXPA04012341A (de)
NO (1)	NO329669B1 (de)
NZ (1)	NZ537044A (de)
PL (1)	PL208711B1 (de)
PT (2)	PT1513835E (de)
RS (2)	RS52588B (de)
TW (2)	TWI283671B (de)
UA (1)	UA77526C2 (de)
WO (2)	WO2003104226A1 (de)
ZA (1)	ZA200409823B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2862967B1 (fr) *	2003-12-01	2006-08-04	Sanofi Synthelabo	Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) *	2003-12-01	2006-08-04	Sanofi Synthelabo	Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
US7723362B2 (en) *	2004-01-08	2010-05-25	Syngenta Crop Protection, Inc.	Pesticidal heterocyclic dihaloallyl compounds
CA2572821A1 (en) *	2004-07-16	2006-01-26	Janssen Pharmaceutica N.V.	Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
MX2007003318A (es) *	2004-09-20	2007-05-18	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
EP2586445A1 (de) *	2005-04-15	2013-05-01	University Of North Carolina At Chapel Hill	Verfahren zur Ermöglichung des Überlebens von Nervenzellen mit Neurotrophin-Mimetika
KR20100049500A (ko) *	2007-03-15	2010-05-12	쉐링 코포레이션	글루칸 신타제 억제제로서 유용한 피리다지논 유도체
JP5466147B2 (ja) *	2007-05-21	2014-04-09	レビバファーマシューティカルズ，インコーポレーテッド	キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
FR2932482B1 (fr) *	2008-06-13	2010-10-08	Sanofi Aventis	Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) *	2008-06-13	2010-10-08	Sanofi Aventis	Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
US10273219B2 (en)	2009-11-12	2019-04-30	Pharmatrophix, Inc.	Crystalline forms of neurotrophin mimetic compounds and their salts
EP3470402B1 (de)	2009-11-12	2021-01-06	Pharmatrophix Inc.	Kristalline formen aus neurotrophinmimetischen verbindungen und deren salzen
MX2012006776A (es)	2009-12-14	2012-10-05	Merck Patent Gmbh	Inhibidores de la esfingosina quinasa.
FR2953839A1 (fr) *	2009-12-14	2011-06-17	Sanofi Aventis	Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) *	2009-12-14	2012-03-16	Sanofi Aventis	Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (de)	2011-12-20	2013-06-26	Sanofi	Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten
EP3684364A4 (de) *	2017-09-18	2021-06-02	Goldfinch Bio, Inc.	Pyridazinone und verfahren zur verwendung davon
MA71645A (fr)	2018-09-18	2025-05-30	Goldfinch Bio, Inc.	Pyridazinones et leurs procédés d'utilisation
US12576033B2 (en)	2019-04-11	2026-03-17	Gfb (Abc), Llc	Spray-dried formulation of a pyridazinone TRPC5 inhibitor
EP3858439A1 (de) *	2020-02-03	2021-08-04	Esteve Pharmaceuticals, S.A.	Amidderivate mit multimodaler aktivität gegen schmerzen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX173180B (es) *	1987-10-26	1994-02-07	Pfizer	Procedimiento para preparar agentes ansioliticos
FR2747041B1 (fr) *	1996-04-05	1998-05-22	Cird Galderma	Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en)	1999-05-17	2002-10-22	Queen's University At Kingston	Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr)	2000-01-06	2002-02-15	Sanofi Synthelabo	Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 RS RS20050014A patent/RS52588B/sr unknown
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr not_active Ceased
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active Expired - Fee Related
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 EP EP03757108A patent/EP1513835B1/de not_active Expired - Lifetime
- 2003-06-05 US US10/516,704 patent/US7468368B2/en not_active Expired - Lifetime
- 2003-06-05 US US10/516,808 patent/US7294628B2/en not_active Expired - Lifetime
- 2003-06-05 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 EP EP03757109A patent/EP1513836B1/de not_active Expired - Lifetime
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr not_active Ceased
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown

Also Published As

Publication number	Publication date
AU2003255644A1 (en)	2003-12-22
US20050176722A1 (en)	2005-08-11
NO20045331L (no)	2005-03-07
CY1105784T1 (el)	2011-02-02
HK1076110A1 (zh)	2006-01-06
AU2003255644B2 (en)	2009-02-05
KR100970812B1 (ko)	2010-07-16
NO329669B1 (no)	2010-11-29
EP1513835B1 (de)	2006-08-16
HRP20041157B1 (en)	2012-11-30
NZ537044A (en)	2006-08-31
BR0311828A (pt)	2005-03-29
UA77526C2 (en)	2006-12-15
EP1513836A1 (de)	2005-03-16
JP2005533051A (ja)	2005-11-04
KR20050008802A (ko)	2005-01-21
ATE336491T1 (de)	2006-09-15
TWI283671B (en)	2007-07-11
CA2487840C (en)	2011-05-17
CN1675203A (zh)	2005-09-28
ES2271637T3 (es)	2007-04-16
IS2302B (is)	2007-10-15
TW200400185A (en)	2004-01-01
DE60305037D1 (de)	2006-06-08
TWI319400B (en)	2010-01-11
IS7579A (is)	2004-12-02
EA200401470A1 (ru)	2005-06-30
RS20050014A (sr)	2007-06-04
HRP20041157A2 (en)	2005-06-30
WO2003104225A1 (fr)	2003-12-18
CA2487840A1 (en)	2003-12-18
EA007501B1 (ru)	2006-10-27
JP4441401B2 (ja)	2010-03-31
WO2003104226A1 (fr)	2003-12-18
DE60307632T2 (de)	2007-08-09
AU2003255645A1 (en)	2003-12-22
TW200407321A (en)	2004-05-16
DK1513835T3 (da)	2006-12-27
DE60307632D1 (de)	2006-09-28
PL208711B1 (pl)	2011-05-31
EP1513836B1 (de)	2006-05-03
PT1513836E (pt)	2006-09-29
MA27233A1 (fr)	2005-02-01
AR040246A1 (es)	2005-03-23
JP2005534661A (ja)	2005-11-17
ZA200409823B (en)	2006-07-26
US20060167007A1 (en)	2006-07-27
CY1107330T1 (el)	2012-11-21
US7294628B2 (en)	2007-11-13
DK1513836T3 (da)	2006-09-11
CN100448875C (zh)	2009-01-07
RS52588B (sr)	2013-04-30
MXPA04012341A (es)	2005-09-30
AR040247A1 (es)	2005-03-23
MEP11508A (en)	2010-06-10
EP1513835A1 (de)	2005-03-16
DE60305037T2 (de)	2006-12-14
PL374729A1 (en)	2005-10-31
ES2264001T3 (es)	2006-12-16
US7468368B2 (en)	2008-12-23
JP4437075B2 (ja)	2010-03-24
PT1513835E (pt)	2006-12-29

Legal Events

Date

Code

Title

Description

2007-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1513836

Country of ref document: EP

Publication	Publication Date	Title
ATE441635T1 (de)	2009-09-15	4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
ATE336491T1 (de)	2006-09-15	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE294171T1 (de)	2005-05-15	Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE310003T1 (de)	2005-12-15	Benzodiazepin-derivate, deren herstellung und anwendung
ATE372998T1 (de)	2007-09-15	1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE409184T1 (de)	2008-10-15	Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE395342T1 (de)	2008-05-15	2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE412635T1 (de)	2008-11-15	Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
DE60336907D1 (de)	2011-06-09	Spirobifluorenderivate, deren herstellung und deren verwendung
DE50312295D1 (de)	2010-02-11	8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE469131T1 (de)	2010-06-15	Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
ATE284886T1 (de)	2005-01-15	Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE319684T1 (de)	2006-03-15	Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE316966T1 (de)	2006-02-15	Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE60235547D1 (de)	2010-04-15	En daraus, deren herstellung und verwendung
DE60208044D1 (de)	2006-01-19	Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60334632D1 (de)	2010-12-02	Mechanolumineszenzstoff und dessen herstellung
IS7829A (is)	2005-04-28	Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
ATE396994T1 (de)	2008-06-15	3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE423119T1 (de)	2009-03-15	Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE69905714D1 (de)	2003-04-10	Platinkomplex, dessen herstellung und dessen therapeutische anwendung
ATE417846T1 (de)	2009-01-15	Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE542806T1 (de)	2012-02-15	Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE474840T1 (de)	2010-08-15	6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE60304596D1 (de)	2006-05-24	In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung